Abstract: Provided are a gene circuit, an RNA delivery system and the use thereof. Specifically, the gene circuit comprises at least an RNA fragment capable of inhibiting gene expression and/or a targeting tag having a targeting function. The gene circuit can be delivered to a host, enriched in organ tissues of the host and self-assembled to form a complex structure, and inhibits gene expression by means of the RNA fragment, thereby treating diseases. The delivery system comprises the gene circuit and a delivery carrier capable of delivering the gene circuit to organ tissues of a host for enrichment. The provided gene circuit has a targeting function and a treatment function, can quickly and accurately reach target organs and target tissues to exert a treatment effect, and is highly efficient with good results. The safety and reliability of the provided RNA delivery system are fully verified, and the RNA delivery system has good druggability, high universality, and great economic benefits and application prospects.

Abstract: This disclosure relates to novel modified oligonucleotides. Novel modified siRNA are also provided.

Abstract: The present invention relates to a nucleic acid molecule encoding a fusion protein comprising a secretion signal comprising (i) a signal peptide sequence originating from a KRE1 protein or a signal peptide sequence originating from a SWP1 protein; and optionally (ii) an ?-mating factor (MF?) pro-sequence, and a protein of interest. The present invention further relates to a secretion signal as defined herein, an expression cassette comprising said nucleic acid molecule as well as recombinant eukaryotic host cells comprising said nucleic acid molecule or expression cassette. Further encompassed is a method of manufacturing a protein of interest in a eukaryotic host cell and a method of increasing the secretion of a protein of interest from a eukaryotic host cell. Further provided is the use of the secretion signal for increasing the secretion of a recombinant protein of interest from a eukaryotic host cell and the use of the recombinant host cell for manufacturing a recombinant protein of interest.

Abstract: Provided herein are chimeric polypeptides for drug-regulated transcriptional repression. Also provided are methods of inhibiting repression of a gene of interest.

Abstract: The invention relates to the production and use of Cas-encoding sequences and vectors comprising these. Aspects of the invention provide products, vectors, delivery vehicles, uses and methods for producing Cas-encoding sequences in bacterial or archaeal cells.

Abstract: The present disclosure relates to the use of recombinant proteins for inducing epigenetic modifications at specific loci, as well as to methods of using these recombinant proteins for modulating the expression of genes in plants.

Abstract: Described herein are methods and compositions for direct genome editing in vivo in plants by targeting cells in the shoot apical meristem.

Abstract: The present disclosure relates to conferring desirable agronomic traits in Legume plants. More particularly, the current invention pertains to producing Legume plants with improved traits by manipulating genes controlling plant architecture.

Abstract: Disclosed herein are agricultural compositions comprising plant messenger packs (PMPs), methods for using the same, and methods and related bioreactors for manufacturing PMPs.

Abstract: This invention is related to a mutated plant line that harbors an impaired LeEIX1 (Lycopersicon esculentum ethylene inducing xylanase receptor 1) gene. The said mutated plant has an increased defense response and a reduction in disease levels upon pathogen exposure compared to a non-mutated plant of the same population. This invention is also related to the method for increasing a plant defense response and for reducing plant diseases levels, comprised by (a) designing at least one nucleic acid sequence configured to targeting and impairing a plant's LeEIX1 gene, (b) applying a gene editing process utilizing said at least one nucleic acid sequence, (c) obtaining at least one mutant plant line, harboring an impaired LeEIX1 gene, (d) growing said plant, and (e) inoculating said plant with at least one bacterial biological control agent.

Abstract: The present disclosure provides compositions and methods for producing transgenic banana plants that exhibit increased resistance to Fusarium oxysporum f.sp. cubense Tropical Race 4 (TR4), and the banana plants and bananas so produced.

Abstract: The present disclosure provides methods and compositions for the improved expression of target proteins via the co-expression of an enhancer protein in a subject. Provided herein are methods for expressing a target protein in a subject comprising administering a vector system of one or more polynucleotides encoding a target protein and an enhancer protein, wherein the polynucleotides are operatively linked, and wherein the enhancer protein is an inhibitor of nucleocytoplasmic transport (NCT) and/or the enhancer protein is selected from the group consisting of a picornavirus leader (L) protein, a picornavirus 2A protease, a rhinovirus 3C protease, a herpes simplex virus (HSV) ICP27 protein, and a rhabdovirus matrix (M) protein.

Abstract: The present disclosure relates generally to immunization and immunotherapy for the treatment or inhibition of HIV. In embodiments, a viral vectors are disclosed that comprise therapeutic cargo portions comprising a nucleotide sequence that encodes at least one soluble exogenous factor capable of inhibiting HIV infection, and a T cell-responsive promoter that regulates expression of the nucleotide sequence.

Abstract: Provided are compositions and methods for transducing immune cells in vivo where a viral particle comprising a polynucleotide encoding a chimeric antigen receptor and a multipartite cell-surface receptor is administered to a subject.

Abstract: Canine distemper vims (CDV) hemagglutinin (H) and fusion (F) polypeptides are provided herein. For example, engineered configurations of CDV fusogenic membrane glycoprotein (FMG) complexes containing H and F glycoproteins are provided herein, as are pseudotyped viruses (e.g., pseudotyped lentiviruses) containing the engineered CDV FMG complexes on their surface. In addition, this document provides nucleic acid molecules encoding CDV-H and/or CDV-F polypeptide components, methods for making recombinant cells expressing the CDV-H and CDV-F polypeptides, and methods for making and using pseudotyped viruses (e.g., pseudotyped lentiviruses) containing CDV FMG complexes.

Abstract: The present disclosure describes methods and systems for use in the production of adeno-associated virus (AAV) particles, including recombinant adeno-associated virus (rAAV) particles. In certain embodiments, the production process and system use Spodoptera frugiperda insect cells (such as Sf9 or Sf21) as viral production cells (VPCs).

Abstract: The present disclosure describes methods and systems for use in the production of adeno-associated virus (AAV) particles, including recombinant adeno-associated virus (rAAV) particles. The production process and system use Baculoviral Expression Vectors (BEVs) and/or Baculoviral Infected Insect Cells (BIICs) in the production of AAV particles (e.g., rAAVs) which allow for the controlled expression of AAV structural (e.g., capsid) proteins, such as VP1, VP2, and VPS and the controlled expression of AAV nonstructural (e.g., replication) proteins, such as Rep78 and Rep52.

Abstract: This invention is directed to AAV compositions for circular RNA expression and methods of expressing covalently closed, circular RNA.

Abstract: Provided are a viral vector-based RNA delivery system and a use thereof. The RNA delivery system comprises a viral vector. The viral vector carries an RNA fragment needing to be delivered, and can be enriched in organ tissues of a host. In the host organ tissues, the viral vector can endogenously and spontaneously form a composite structure containing the RNA fragment. The composite structure can enter and bind to target tissues, and feed the RNA fragment into the target tissues. The viral vector has a targeting tag. The composite structure is an exosome. The viral vector RNA delivery system is safe and reliable, and has good druggability and high universality.

Abstract: A lentiviral vector system for expressing a lentiviral particle is disclosed. The lentiviral vector system includes a therapeutic vector. The therapeutic vector comprises a phenylalanine hydroxylase (PAH) sequence for expressing at least one of PAH or a variant thereof, wherein the PAH sequence is truncated.

Abstract: The present disclosure provides methods and compositions comprising novel Cas TypeV programmable nucleases and lipid nanoparticles capable of delivering the Cas TypeV programmable nucleases and genome editing systems comprising same. For therapeutic applications, as well as plants and industrial biotechnology.

Abstract: The present disclosure provides the vector constructs comprising (a) a polynucleotide comprising a promoter operably linked to a nucleic acid of interest; (b) a first terminal repeat and a second terminal repeat; and (c) a backbone polynucleotide comprising a nucleic acid sequence that modulates a Toll-like receptor (TLR). Some aspects of the disclosure are related to methods for packaging the nucleic acid of interest and the nucleic acid sequence that modulates the TLR in an AAV particle, and some aspects are related to methods of modulating an immune response in a subject, comprising administering to said subject an effective amount of such AAV particles.

Abstract: Provided herein, in some embodiments, are nucleic acid constructs encoding therapeutic proteins of interest comprising one or more alternatively-spliced exons that regulate the expression of therapeutic proteins of interest. Such constructs may in some embodiments be useful for delivery in a recombinant viral vector.

Abstract: This invention provides methods and systems for enhancement of protein production from mammalian cell lines in a drug inducible manner. The methods described herein can be used to generate a protein production cell line wherein the gene coding the protein product of interest is inserted into specific safe harbor loci (SHL) within the cell's genome and the gene copy number is induced to amplify by the use of an antibiotic inducer. The method enables for the conditional activation of the drug inducible transposase. The drug inducible gene amplification method described herein effectively functions as a molecular dial: combining drug-inducible homologous recombination and conditional gene activation to fine-tune gene amplification in mammalian systems.

Abstract: Nucleic acids and viral vectors, particularly adeno-associated virus (AAV) vectors are provided that encode Cas9 and paired guide RNAs. The nucleic acids and vectors, and compositions that comprise them, can be used in methods to treat subjects, to alter cells in subjects who may suffer from an inherited retinal dystrophy such as CEP290 associated disease or who may be in need of alteration of a cell or a cellular nucleic acid sequence associated with an inherited retinal dystrophy such as the CEP290 gene, and/or to treat inherited retinal dystrophies including CEP290 associated disease.

Abstract: Provided herein, in some embodiments, are engineered nucleic acid targeting vectors that include a sequence of interest flanked by homology arms, each homology arm comprising a sequence homologous to a sequence in a safe harbor site in the human genome in any one of the following loci: 1q31, 3p24, 7q35, and Xq21. Also provided herein are methods of using and compositions the comprising engineered nucleic acid targeting vectors.

Abstract: The present invention relates to variant polypeptides, methods of preparing the variant polypeptides, processes for characterizing the variant polypeptides, compositions and cells comprising the variant polypeptides, and methods of using the variant polypeptides. The invention further relates to complexes comprising the variant polypeptides, methods of producing the complexes, processes for characterizing the complexes, cells comprising the complexes, and methods of using the complexes.

Abstract: Described herein are systems and methods for treating, inhibiting, or ameliorating X-linked disorders including Wiskott-Aldrich Syndrome (WAS) and X-linked thrombocytopenia (XLT) in subjects that have been identified or selected as being ones that would benefit from a therapy to treat, inhibit, or ameliorate WAS or XLT. The systems include nuclease and vector donor constructs configured for co-delivery to modify endogenous WAS locus.

Abstract: A method for preparing a fiber material from a banana pseudostem, which includes subjecting the banana pseudostem to a pressing treatment to obtain a pressed banana pseudostem, subjecting the pressed banana pseudostem to a fermentation reaction with Saccharomyces cerevisiae to obtain a fermented culture, subjecting the fermented culture to a simultaneous saccharification and fermentation process with pectinase to obtain a fermented product, subjecting the fermented product to a solid-liquid separation treatment to obtain a solid fraction, and subjecting the solid fraction to an alkali treatment, a water washing treatment, a bleaching treatment, a softening treatment, and a drying treatment in sequence, so as to obtain the fiber material.

Abstract: Producing a composition comprising cells of at least one bacterium, where at least 90% of the composition is in the form of a free flowing powder, by providing a drum dryer comprising two spaced-apart rotatable cylinders, with a gap of width G inches and a length of L inches therebetween; providing a fermentation broth comprising cells of at least one bacterium in a liquid suspension at a total solid content C percent weight of no greater than about 15% wt of the total weight of the fermentation broth; and introducing the fermentation broth into said drum dryer at a rate of W Kg per hour of no greater than 14×[(G×L)/C] to provide the composition.

Abstract: The present disclosure relates to methods for producing oxygenated terpenoids, and preparation of compositions and formulations thereof. Polynucleotides, derivative enzymes, and host cells for use in such methods are also provided.

Abstract: Disclosed herein are methods of reducing and/or preventing “greening” in sunflower-containing food products.

Abstract: The present invention relates to a process of recovering 3-hydroxypropionic acid, comprising: forming a 3-hydroxypropionate crystal in a concentrate containing 3-hydroxypropionic acid in the presence of an alkali metal salt, preparing a solution containing 3-hydroxypropionate crystal separated from the concentrate, stirring an acid and the solution containing 3-hydroxypropionate crystal to form a precipitate, and subjecting the precipitate to a first washing, and a slurry composition comprising a precipitate prepared in the process of recovering 3-hydroxypropionic acid and 3-hydroxypropionic acid.

Abstract: The present invention relates to an oil of microorganisms rich in docosahexaenoic acid (DHA, C22:6n3), comprising more than 60% of DHA relative to the total mass of fat and to the use thereof for human or animal feed, in particular for feeding infants, children, or pregnant or lactating women.

Abstract: A method for producing ergothioneine or a related substance, where the method includes culturing a microorganism having an ergothioneine biosynthetic gene with an increased adenosine kinase (Adk) activity, and collecting the ergothioneine, a related substance thereof, or a mixture thereof from the medium obtained by the culture or the bacterial cells.

Abstract: Provided herein are non-naturally occurring microbial organisms having biosynthetic pathways for production of target products and one or more genetic modifications that reduce a byproduct of the biosynthetic pathway. Compositions of target products from such cells and methods of using such cells are provided.

Abstract: A production method of low molecular weight ?-glucan includes: inoculating an activated Leuconostoc mesenteroides in a 5 L fermentor at a 10% inoculum. Fermentation broth is placed in the fermentor at an initial pH of 6.8-7.0, temperature of 25° C. to 28° C., stirring speed at 120 r/min, and fermented for 20-40 hours. Dextranase is added after 5-30 hours of fermentation at a dosage of 1/10,000 to 5/10,000 by volume. The molecular weight of ?-glucan is controlled within 10000D by the amount of enzyme added, and the total fermentation process is about 20-40 hours. After the reaction is terminated, the fermentation liquid is concentrated and dried to prepare dietary fiber products with a molecular weight of 500-5000D. The viscosity of the fermentation liquid and concentration of ?-glucan in the fermentation liquid may be reduced to promote the forward reaction, accelerate the sucrose conversion rate and increase the product yield.

Abstract: Provided herein are methods for generating multiplex CRISPR arrays based on annealing and ligating single-stranded DNA oligonucleotides using bridge oligonucleotides. The methods described herein include providing a first oligonucleotide comprising a CRISPR repeat sequence or a portion thereof, and a first portion of a first spacer sequence at its 3? end; providing a second oligonucleotide comprising, from 5? to 3?, a second portion of the first spacer sequence, the CRISPR repeat sequence, and a first portion of a second spacer sequence; providing a bridge oligonucleotide comprising a sequence substantially complementary to the first spacer sequence; allowing the first oligonucleotide and the second oligonucleotide to hybridize with the bridge oligonucleotide; and ligating the first and second oligonucleotide.

Abstract: A method, which synthesizes closed circular single-stranded and double-stranded DNA molecules using in vitro enzymatic systems, is described. Circular single-stranded DNA molecules and double-stranded DNA molecules (e.g., relaxed, or supercoiled) with various sizes can be synthesized. Unwanted DNA molecules, e.g., unligated oligomers, can be removed by exonucleases, such as T5 exonuclease, T7 exonuclease, lambda exonuclease, E. coli exonuclease I and/or III. A method of converting the single-stranded circular DNA molecules into double-stranded circular DNA molecules is also described. The single-stranded and double-stranded circular DNA molecules can be used in a variety of applications.

Abstract: Glycoproteins having particular sialylation patterns, and methods of making and using such glycoproteins, are described.

Abstract: An object of the present invention is to provide a protein having dipeptide synthesizing activity with improved substrate specificity, and a method in which the protein or a microorganism having ability to produce the protein is used to efficiently produce a target dipeptide while reducing a by-product dipeptide produced in addition to the target dipeptide. According to the present invention, a protein consisting of an amino acid sequence obtained by substituting, with other amino acid residues, amino acid residues corresponding to one or more amino acid residues selected from the group consisting of amino acid residues at positions 107, 108, and 110 in an amino acid sequence set forth in SEQ ID NO: 2, or a mutant protein or a homologous protein of a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 is provided, and a microorganism producing the protein can be used to efficiently produce a dipeptide.

Abstract: Recombinant proteins comprising a non-canonical amino acid with high yield and high fidelity are made by expressing the protein in an engineered Vibrio natriegens strain containing an orthogonal translation system comprising an orthogonal aminoacyl tRNA synthetase that charges the non-canonical amino acid onto the orthogonal cognate tRNA.

Abstract: A polymer included in a reagent layer of a sensor for measuring an analyte in a sample includes: a first binding site covalently bonded to a protein acting on the analyte; and a second binding site that binds to the protein by electrostatic interaction.

Abstract: The composition, kit and information provision method, according to an aspect of the present invention, may predict or diagnose early-stage diffuse-type gastric cancer with high sensitivity and specificity when the level of serum pepsinogen II is equal to or greater than 20 ?g/L, and further, may classify the risk of early-stage diffuse-type gastric cancer in a subject on the basis of whether the level of serum pepsinogen II is equal to or greater than 20 ?g/L and whether the status of Helicobacter pylori (HP) is positive, and thus, the composition, comprising a preparation capable of measuring the level of serum pepsinogen II, or, along with said preparation, a preparation capable of detecting the status of HP, the kit and the information provision method using same have an excellent effect of being capable of being usefully employed as non-invasive means which may be carried out prior to an endoscopy.

Abstract: A method for quantifying at least one microorganism group via at least one mass spectrometry analysis. The method includes at least one separation and fragmentation step. The method moreover includes a step that involves measuring the amount of at least one representative peptide or at least one protein representing the microorganism group. The at least one representative peptide or the at least one protein is obtained after the at least one separation and fragmentation step and serves as a quantification marker(s). The amount of the quantification marker(s) is directly correlatable to the amount of the at least one microorganism group.

Abstract: Described herein are methods for characterizing the age of an insect fecal pellet, where the method can comprise: (1) obtaining insect fecal pellet material to be tested; (2) exposing the pellet material to an H2O2 solution; and (3) detecting the presence of generated oxygen, where the amount of oxygen generated is inversely proportional to the age of the insect pellet. Also described are kits for carrying out the method.

Abstract: Described herein are cell-based high-throughput screening (HTS) assays for the identification of activators of ?-secretase.

Abstract: The present disclosure relates to methods, compositions, and kits for concentrating and purifying at least one target analyte from a clinical biological sample. In some embodiments, the methods involve one or more aqueous two-phase system (ATPS) compositions and at least one solid phase medium. Some embodiments provide a kit comprising one or more ATPS compositions, a binding buffer; and a solid phase medium. Other embodiments provide methods of treating cancers or infectious diseases in a patient in need thereof.

Abstract: The present invention relates to the field of biotechnology, more specifically to the field of molecular diagnostics, more specifically to a method for the detection of a polynucleotide of interest in a sample.

Abstract: Provided herein, in some aspects, is a multiplex RNA targeting system that enables live cell imaging and/or modification of multiple RNA targets. Specifically, the disclosure provides a method of live cell imaging of ribonucleic acid (RNA), or targeting RNA in a live cell, comprising: (a) delivering to a cell an RNA-editing complex that comprises a catalytically inactive Cas13 (dCas13) nuclease, a Cas 13 guide RNA (gRNA) comprising an RNA aptamer sequence, and a detectable molecule linked to an RNA-binding domain (RBD), or an RNA effector molecule linked to an RBD sequence that specifically binds to the RNA aptamer sequence; and (b) imaging the detectable molecule or RNA aptamer and RBD binding.